The discovery and development of an efficient, practical asymmetric sy
nthesis of the HIV Protease inhibitor CRIXIVAN(R) is described. Partic
ular emphasis is placed on the selective installation of each of the f
ive stereogenic centers as well as design strategies associated with t
he preparation of a complex pharmaceutical agent needed in multiton qu
antities.